EFM
E Fund Management Portfolio holdings
AUM
$2.1B
This Quarter Return
+14.76%
1 Year Return
+23.31%
3 Year Return
+155.42%
5 Year Return
–
10 Year Return
–
AUM
$2.1B
AUM Growth
+$2.1B
(+0.21%)
Cap. Flow
-$186M
Cap. Flow
% of AUM
-8.85%
Top 10 Holdings %
Top 10 Hldgs %
51.83%
Holding
429
New
31
Increased
85
Reduced
265
Closed
35
Top Buys
| 1 |
abrdn Physical Gold Shares ETF
SGOL
|
$20M |
| 2 |
iShares Gold Trust
IAU
|
$19.8M |
| 3 |
SPDR Gold MiniShares Trust
GLDM
|
$19.6M |
| 4 |
SPDR Gold Trust
GLD
|
$19.6M |
| 5 |
Invesco DB Oil Fund
DBO
|
$11M |
Top Sells
| 1 |
KE Holdings
BEKE
|
$70.4M |
| 2 |
Futu Holdings
FUTU
|
$37.4M |
| 3 |
Apple
AAPL
|
$18.8M |
| 4 |
Microsoft
MSFT
|
$13.6M |
| 5 |
Applied Materials
AMAT
|
$11.3M |
Sector Composition
| 1 | Technology | 43.87% |
| 2 | Consumer Discretionary | 23.94% |
| 3 | Communication Services | 11.36% |
| 4 | Healthcare | 5.11% |
| 5 | Financials | 3.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
MannKind Corp
MNKD
$1.41B
| $98K | ﹤0.01% |
26,196
+1,529
| +6% | +$5.72K |
|
377
Anavex Life Sciences
AVXL
$828M
| $94.6K | ﹤0.01% |
10,259
-1,652
| -14% | -$15.2K |
|
378
Arcus Biosciences
RCUS
$1.13B
| $89.4K | ﹤0.01% |
10,987
+489
| +5% | +$3.98K |
|
379
Xencor
XNCR
$580M
| $79.3K | ﹤0.01% |
+10,087
| New | +$79.3K |
|
380
ImmunityBio
IBRX
$2.21B
| $74.2K | ﹤0.01% |
28,108
-2,223
| -7% | -$5.87K |
|
381
Vir Biotechnology
VIR
$686M
| $74.1K | ﹤0.01% |
14,698
-1,295
| -8% | -$6.53K |
|
382
Cogent Biosciences
COGT
$1.69B
| $73.3K | ﹤0.01% |
10,205
-5,465
| -35% | -$39.2K |
|
383
Day One Biopharmaceuticals
DAWN
$769M
| $71.4K | ﹤0.01% |
10,988
-148
| -1% | -$962 |
|
384
Relay Therapeutics
RLAY
$619M
| $70.1K | ﹤0.01% |
20,258
+1,093
| +6% | +$3.78K |
|
385
Kura Oncology
KURA
$686M
| $67.5K | ﹤0.01% |
11,702
-550
| -4% | -$3.17K |
|
386
Myriad Genetics
MYGN
$593M
| $66.8K | ﹤0.01% |
12,575
-1,145
| -8% | -$6.08K |
|
387
Cboe Global Markets
CBOE
$24.7B
| $59.7K | ﹤0.01% |
+256
| New | +$59.7K |
|
388
Iovance Biotherapeutics
IOVA
$807M
| $56K | ﹤0.01% |
32,559
-6,835
| -17% | -$11.8K |
|
|
NIU
389
Niu Technologies
NIU
$341M
| $53.8K | ﹤0.01% |
+16,000
| New | +$53.8K |
|
390
Verastem
VSTM
$569M
| $48.6K | ﹤0.01% |
+11,700
| New | +$48.6K |
|
391
Altimmune
ALT
$338M
| $44K | ﹤0.01% |
11,357
-2,070
| -15% | -$8.01K |
|
392
Humacyte
HUMA
$245M
| $43.1K | ﹤0.01% |
20,625
+3,492
| +20% | +$7.3K |
|
|
HUYA
393
Huya Inc
HUYA
$796M
| $36.6K | ﹤0.01% |
+10,399
| New | +$36.6K |
|
394
Taysha Gene Therapies
TSHA
$797M
| $30.5K | ﹤0.01% |
+13,214
| New | +$30.5K |
|
395
ACM Research
ACMR
$1.81B
| – | – |
-34,800
| Closed | -$812K |
|
396
Agios Pharmaceuticals
AGIO
$2.19B
| – | – |
-8,750
| Closed | -$256K |
|
397
Akamai
AKAM
$11.3B
| – | – |
-3,049
| Closed | -$245K |
|
398
Aon
AON
$79.1B
| – | – |
-546
| Closed | -$218K |
|
399
argenx
ARGX
$43.6B
| – | – |
-5,800
| Closed | -$3.43M |
|
400
Atour Lifestyle Holdings
ATAT
$5.38B
| – | – |
-48,532
| Closed | -$1.38M |
|